Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | WDR5 | P61964 | 1/20 | 0.42 |
| ▸ | CTSD | P07339 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4923478 | 0.92 | ALDH1A1 (0.55) | PPARGALDH1A1POLBGAAATM | |
| SCHEMBL4922466 | 0.87 | TSHR (0.52) | ALDH1A1POLBGAAKMT2AMEN1 | |
| SCHEMBL4924613 | 0.87 | SMN1; SMN2 (0.49) | ALDH1A1POLBGAAHTR2ASMN1; SMN2 | |
| SCHEMBL4917788 | 0.87 | LMNA (0.49) | ALDH1A1POLBGAASMN1; SMN2MCHR1 | |
| SCHEMBL4920792 | 0.86 | SMN1; SMN2 (0.49) | ALDH1A1POLBGAASMN1; SMN2LMNA | |
| SCHEMBL4922442 | 0.86 | ALDH1A1 (0.47) | ALDH1A1POLBGAAATMSMN1; SMN2 | |
| SCHEMBL4921293 | 0.85 | ALDH1A1 (0.55) | PPARGALDH1A1POLBGAAATM | |
| SCHEMBL4921996 | 0.85 | ALDH1A1 (0.50) | PPARGALDH1A1KMT2AMEN1HTR2A | |
| SCHEMBL4917345 | 0.84 | SMN1; SMN2 (0.47) | ALDH1A1POLBGAASMN1; SMN2LMNA | |
| SCHEMBL4924218 | 0.83 | CCR5 (0.49) | ALDH1A1POLBGAAKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080081824-A1 | Substituted piperidines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2008-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080081824-A1 | Substituted piperidines as modulators of chemokine receptor activity | CCR1, CCR3, CCR2 | PPARG 468/4885ALDH1A1 1255/4885POLB 2562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.